Hims & Hers Health, Inc.

HIMS Healthcare Drug Manufacturers Specialty & Generic

Hims & Hers Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 59.0% from fiscal 2024.

Revenue
+38.3%
EPS
−294.7%
Free cash flow
+5.09%
Total debt
+40.8%

Quarter to June 2026, against a year earlier

25.27 1.21 +5.03%
Market cap
$5.6B
P/E
0.0×
Fwd P/E
−49.4×
Dividend yield
—
F-score
4/9
Altman Z
4.10
Beneish M
n/a
Dividend safety
n/a

Hims & Hers Health, Inc. 8-K filed May 19, 2026

Period ended May 18, 2026 · Filed · accepted 8:17 AM ET · Document on sec.gov · Filing index

8.01 Other events; 9.01 Financial statements and exhibits

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov